Hanmi’s IMD pidogul approved in Italy

Published: 2012-01-10 06:56:00

Updated: 2012-01-10 06:56:00

Hanmi Pharmaceutical announced Monday that the firm received an approvable letter for Pidogul (clopidogrel napadisilate monohydrate) tablets, one of its incrementally modified drugs (IMDs), from Italian health authorities, following the first approval from Britain’s health watchdog the Medicines ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK